호르몬 대체요법과 안 질환: 제4기 국민건강영양조사자료
Hormone Replacement Therapy and Eye Diseases: KNHANES IV
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
목적: 호르몬대체요법과 안질환의 관계를 밝히고자 하였다. 대상과 방법: 5,808명의 제4기 국민건강영양조사를 완료한 여성중 호르몬 대체요법 시행 군과 받지 않은 군 간의 안질환 유병을 회귀분석을 통한 보정 평균을 비교하였다. 결과: 호르몬 대체요법을 시행 받은 군의 수는 480명(8.3%)이었고, 근시는 호르몬대체요법을 시행 군에서 44.5% (95%CI, 38.1-51.2),시행 받지 않은 군에서 54.4% (95%CI, 52.6-56.1)이며, 원시는 시행 군에서 7.7% (95%CI, 5.5-10.6), 시행 받지 않은 군에서 4.5%(95%CI, 3.8-5.3)이며, 익상편은 시행 군에서 2.1% (95%CI, 1.3-3.3), 시행 받지 않은 군에서 3.3% (95%CI, 2.7-4.0)로 p-value 0.05미만의 통계적 유의한 차이를 보였고, 당뇨망막증은 시행 군에서 5.6% (95%CI, 1.4-19.8), 시행 받지 않은 군에서 16.7% (95%CI,13.0-21.2)로 p-value 0.053으로 통계적으로 의미 있는 경계에 놓여 있었다. 결론: 호르몬대체요법 시행 군에서 근시, 익상편과 당뇨망막증은 적었고, 원시는 많았다.
Abstract
Purpose: To identify the association between hormone replacement therapy and eye diseases. Methods: The fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) is a nationwide survey. The study included 5,808 females who completed the KNHANES IV. The prevalence of eye disease of adjusted mean using linear regression analysis between the subjects who had hormone replacement therapy and those who did not have the therapy was analyzed. Results: Among the 5,808 females, 480 (8.3%) received hormone replacement therapy. The adjusted prevalence of myopia was 44.5% (95% CI, 38.1-51.2) in the subjects who received hormone replacement therapy, and 54.4% (95% CI,52.6-56.1) in those who did not have the therapy. The adjusted prevalence of hyperopia was 7.7% (95% CI, 5.5-10.6) in subjects who received hormone replacement therapy and 4.5% (95% CI, 3.8-5.3) in those who did not have the therapy. The adjusted prevalence of pterygium was 2.1% (95% CI, 1.3-3.3) in the subjects who received hormone replacement therapy and 3.3% (95% CI, 2.7-4.0) in those who did not have the therapy. All the results were statistically significant with a p-value <0.05. The adjusted prevalence of diabetic retinopathy was 5.6% (95% CI, 1.4-19.8) in the subjects who received hormone replacement therapy and 16.7% (95% CI, 13.0-21.2) in those who did have the therapy. The p-value was 0.053, which is marginally statistically significant. Conclusions: The adjusted prevalence of myopia, pterygium, and diabetic retinopathy in the subjects who received hormone replacement therapy was low, although hyperopia was statistically significantly high.
참고문헌 (28)
- Rockman CB, "Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women", Ann Vasc Surg, 26, pp.411~418 (2012)
- Sator MO, "Reduction of intraocular pressure in a glaucoma patient undergoing hormone replacement therapy", Maturitas, 29, pp.93~95 (1998)
- Freeman EE, "Incidence and progression of lens opacities: effect of hormone replacement therapy and reproductive factors", Epidemiology, 15, pp.451~457 (2004)
- Younan C, "Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study", Am J Epidemiol, 155, pp.997~1006 (2002)
- Kanthan GL, "Exogenous oestrogen exposure, female reproductive factors and the long-term incidence of cataract: the Blue Mountains Eye Study", Acta Ophthalmol, 88, pp.773~778 (2010)
- Klein BE, "Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy", Diabetes Care, 22, pp.1984~1987 (1999)
- Erdem U, "Effect of hormone replacement therapy in women on ocular refractive status and aberrations", J Refract Surg, 23, pp.567~572 (2007)
- Edwards DR, "Inverse association of female hormone replacement therapy with age-related macular degeneration and interactions with ARMS2 polymorphisms", Invest Ophthalmol Vis Sci, 51, pp.1873~1879 (2010)
- Freeman EE, "Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project", Ophthalmic Epidemiol, 12, pp.37~45 (2005)
- Smith W, "Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study", Aust N Z J Ophthalmol, 25(Suppl 1), pp.13~15 (1997)
- Erdem U, "Dry eye in post-menopausal women using hormone replacement therapy", Maturitas, 56, pp.257~262 (2007)
- Mathers WD, "The effect of hormone replacement therapy on the symptoms and physiologic parameters of dry eye", Adv Exp Med Biol, 506, pp.1017~1022 (2002)
- Barney NP, "Can hormone replacement therapy cause dry eye?", Arch Ophthalmol, 120, pp.641~642 (2002)
- Schaumberg DA, "Hormone replacement therapy and dry eye syndrome", JAMA, 286, pp.2114~2119 (2001)
- 문정현, "폐경기 여성의 호르몬 대치요법이 안구건조증상에 미치는 영향: 전향적 연구보고", 대한안과학회지, 51(2), pp.175~179 (2010), 대한안과학회
- Kyung-Chul Yoon, "Prevalence of Eye Diseases in South Korea: Data from the Korea National Health and Nutrition Examination Survey 2008-2009", Korean Journal of Ophthalmology, 25(6), pp.421~433 (2011), 대한안과학회
- Huang KE, "Updated clinical recommendations for the use of tibolone in Asian women", Climacteric, 13, pp.317~327 (2010)
- Jeong Namkung, "The Survey on Korean Menopausal Women’s Behavior and Perception of Hormone Therapy", 대한폐경학회지, 17(3), pp.142~149 (2011), 대한폐경학회[DOI]
- Maclennan AH, "Hormone replacement therapy: Prevalence, compliance and the ‘healthy women’ notion", Climacteric, 1, pp.42~49 (1998)
- Connelly MT, "Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990-1995", J Gen Intern Med, 15, pp.542~550 (2000)
- Sharma S, "Refractive issues in pregnancy", Aust N Z J Obstet Gynaecol, 46, pp.186~188 (2006)
- Affinito P, "Effects of hormone replacement therapy on ocular function in postmenopause", Menopause, 10, pp.482~487 (2003)
- Ishioka M, "Pterygium and dry eye", Ophthalmologica, 215, pp.209~211 (2001)
- Rajiv, Mithal S, "Pterygium and dry eye--a clinical correlation", Indian J Ophthalmol, 39, pp.15~16 (1991)
- Glacet-Bernard A, "Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy", Contracept Fertil Sex, 27, pp.285~290 (1999)
- Arroyo J., "Age-related eye diseases: impact of hormone replacement therapy, and reproductive and other risk factors", Int J Fertil Womens Med, 45, pp.301~313 (2000)
- Sator MO, "Hormone replacement therapy and intraocular pressure", Maturitas, 28, pp.55~58 (1997)
- Uncu G, "The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity", Gynecol Endocrinol, 22, pp.501~505 (2006)